Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
With all the dullards claiming they wouldn’t accept a £2/3 per share TO bid, would they like to enlighten us with some examples of listed targets being acquired and many multiples / premiums on current share price?
Whilst noting the markets are far from perfect, I frankly find it laughable to suggest even £2 per share would be offered at our current paltry MCap.
Spot on. Don’t worry about reality, just read Tom the bomb and RAH and hold for the 20Bn TO.
Takeovers can leak many weeks before they happen, just like placings. There are many examples of stocks rallying up to the actual event.
Literally beyond parody these numpties saying they wouldn’t accept £2 - a c500% premium on current market value hahahahhaahaaaaaaa
Also - interesting that none of the £10bn crew can answer the question????
Cyma bay, $2 in 2022 and bought for $4,43 bn this February at $30 a share.
MorphoSys $12 a share 2023, bought for $67 a share q1 2024.
Harry is from Grimsby and runs a dry-cleaning business. Based on his comprehensive knowledge of the science (and comments from a discredited former CEO), he is in no doubt that it works, it’s the holy grail.
BP are much less convinced than Harry and aren’t throwing sack loads of money to buy out AVCT.
Stupid BPs, they need to be more like Harry.
Rarely agree with MM but "perilous situation" feels apt
Fusion pharmaceuticals $2.48 in September last year, sold for $21.53 in April this year.
And those are just three of the deals done this year. There’s no doubt biotech businesses can attract many multiples and they are valued for acquisitions on the potential revenue their drugs or platforms can achieve many years in the future.
SP has little correlation with TO value.
Would you fire a CEO a few weeks or months away from a TO?
The answer is no. It can be said, with certainty, that there will be no TO for the foreseeable future. It's safe to assume that no TO talks have even begun. Plus, any prospective buyers will be scratching their heads and trying to figure out why the incompetant BOD didn't remove the CEO sooner.
That’s what you think 💭
How wrong assumptions can be by trying to use logic to create fact.
The problem is the logic!
Watch this space. The program the data and the general knowledge of what is growing here is very well known by BP. The irrelevant bit is PI’s assumptions of understanding what this company sits on in value to these majors.
It’s huge.
Ambrx $4 in October sold for $28 this year.
CEO didn’t want a T/O just wanted to carry on with £500k salary pa and 1 million share options from abacus Tony.
Question should be how many companies did he ignore to keep his life style.
So yes CC could now be in T/O talks
Bang on Energy.
Sage - you’re half right. Those claiming they’d turn down £3 tomorrow are deluded.
That said, are you being genuine or just using it to have a pop at Tom et al?
What would you say fair value is, as we sit today.
Bein - a bit of both. The twitteratii do my head in, truth be told. Beyond help in their delusions.
Fair value today? Really difficult question given I’m not a scientist and instead am from a finance background.
I would say somewhere between £1-1.40 is a fair reflection, but that could obviously change (overnight) on material good or bad news….
I see your reasoning from a financial perspective, it is mad to think we’d be approached for £10 from here. But there lies the problem - I do believe we’re disconnected from reality and the SP destruction stopped that ‘dream’ in the near term.
Here’s hoping CC steers it more toward that higher number.
Oh it’s coming!!!
The largest multiple to current share price for a major buying a small biotech company in the UK in recent years was **42x**. This was paid by **AstraZeneca** for **Alexion Pharmaceuticals** in 2021.
Other notable examples of high multiples paid for small biotech companies in the UK include:
* **GSK** acquired **Sierra Oncology** for **36x** its current share price in 2022.
* **Johnson & Johnson** acquired **Actelion Pharmaceuticals** for **30x** its current share price in 2017.
* **Roche** acquired **Spark Therapeutics** for **29x** its current share price in 2019.
These high multiples reflect the strong demand for promising biotech companies by large pharmaceutical companies. Biotech companies often have valuable pipelines of new drugs and technologies, which can be attractive to larger companies looking to expand their portfolios.
It is important to note that these are just a few examples, and the multiples paid for small biotech companies can vary depending on a number of factors, such as the size of the company, the stage of its development, and the potential of its pipeline.
What's the average and what percentage went bust?
Or are you cherry picking?
Ok, I’ll take 42x.
CC will have seen the questions, seen the vitriol thrown at Al via investormeet. She’ll need to show something at the AGM. Another regurgitation and can kicking won’t cut it. A well communicated strategy is needed. Lassos and six shooters available for sale….
I’d prefer this:
https://en.wikipedia.org/wiki/Heckler_%26_Koch_HK416
Latest bizarre fud angle completely discredited. Still I’m happy they’re admitting the share will be sold for multiples of its current value, it makes a change from the usual mindless shouty tramp effluvia.
Regarding the multiple, Avacta have a platform proven to target the tumour environment with scope for multiple warheads while avoiding off target toxicity - the holy grail. It opens up the potential for previously discarded drugs that were too toxic to be revisited, off patent drugs to be patented and a plethora of combination therapy opportunities.
It has huge potential. Then there’s the pathfinder which is potentially only 18-24 months from approval.
The multiple will be 10x plus current sp, but could be driven far higher with competing offers. All imo.
NFTs.
Notably the most relevant point for parient awaiters!
Majority of purchased later stagers ( in 24) ,and similarities with Av.
CEO openly stated Development of commercial links ‘ very busy ‘.
Let’s see what it’s worth at this stage.
My take AS not in agreement with deals coming forward at this point.
Time will tell..
GLA
At this rate a multiple of 42x will end up getting me to break even! 😜 GLALTH
Why would any sensible CEO of big pharma pay a crazy double digit x SP for Avacta when his advisers would tell him the AV shareholders would fall over themselves at present to accept something like 125p? Yes, such a bid might set off a bidding war, but only might.